KRAS and neoplasm: Tumor molecular markers, such as CpG island methylator phenotype (CIMP) status; driver gene mutations, such as KRAS and BRAF; and tumor immune microenvironment, have been linked to different recurrence risks among stage III colon cancer patients (Auclin et al., 2017; Murcia et al., 2018).